We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.

2ooh

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:2ooh.jpg|left|200px]]
+
{{Seed}}
 +
[[Image:2ooh.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_2ooh| PDB=2ooh | SCENE= }}
{{STRUCTURE_2ooh| PDB=2ooh | SCENE= }}
-
'''Crystal Structure of MIF bound to a Novel Inhibitor, OXIM-11'''
+
===Crystal Structure of MIF bound to a Novel Inhibitor, OXIM-11===
-
==Overview==
+
<!--
-
Pharmacophores are chemical scaffolds upon which changes in chemical moieties (R-groups) at specific sites are made to identify a combination of R-groups that increases the therapeutic potency of a small molecule inhibitor while minimizing adverse effects. We developed a pharmacophore based on a carbonyloxime (OXIM) scaffold for macrophage migration inhibitory factor (MIF), a protein involved in the pathology of sepsis, to validate that inhibition of a catalytic site could produce therapeutic benefits. We studied the crystal structures of MIF.OXIM-based inhibitors and found two opposite orientations for binding to the active site that were dependent on the chemical structures of an R-group. One orientation was completely unexpected based on previous studies with hydroxyphenylpyruvate and (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester (ISO-1). We further confirmed that the unexpected binding mode targets MIF in cellular studies by showing that one compound, OXIM-11, abolished the counter-regulatory activity of MIF on anti-inflammatory glucocorticoid action. OXIM-11 treatment of mice, initiated 24 h after the onset of cecal ligation and puncture-induced sepsis, significantly improved survival when compared with vehicle-treated controls, confirming that inhibition of the MIF catalytic site could produce therapeutic effects. The crystal structures of the MIF inhibitor complexes provide insight for further structure-based drug design efforts.
+
The line below this paragraph, {{ABSTRACT_PUBMED_17526494}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 17526494 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_17526494}}
==Disease==
==Disease==
Line 31: Line 35:
[[Category: Alternative ligand-binding mode]]
[[Category: Alternative ligand-binding mode]]
[[Category: Isomerase]]
[[Category: Isomerase]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 11:19:49 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 19:51:15 2008''

Revision as of 16:51, 28 July 2008

Image:2ooh.png

Template:STRUCTURE 2ooh

Contents

Crystal Structure of MIF bound to a Novel Inhibitor, OXIM-11

Template:ABSTRACT PUBMED 17526494

Disease

Known disease associated with this structure: Persistent Mullerian duct syndrome, type I OMIM:[600957], Rheumatoid arthritis, systemic juvenile, susceptibility to OMIM:[153620]

About this Structure

2OOH is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.

Reference

Alternative chemical modifications reverse the binding orientation of a pharmacophore scaffold in the active site of macrophage migration inhibitory factor., Crichlow GV, Cheng KF, Dabideen D, Ochani M, Aljabari B, Pavlov VA, Miller EJ, Lolis E, Al-Abed Y, J Biol Chem. 2007 Aug 10;282(32):23089-95. Epub 2007 May 25. PMID:17526494

Page seeded by OCA on Mon Jul 28 19:51:15 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/2ooh"
Personal tools